<DOC>
	<DOCNO>NCT02960620</DOCNO>
	<brief_summary>This research study . The purpose provide supervise access TheraSphere® therapy institution .</brief_summary>
	<brief_title>Therasphere Unresectable Primary Secondary Liver Neoplasia</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>Patients recruit patient population refer principal clinician regional liver cancer therapy . Potential candidate diagnose primary secondary liver neoplasia . The histopathology confirmation criterion may waive patient radiographically identifiable liver mass , know laboratory clinical risk factor cancer elevate tumor marker clinical finding . Guidelines American Association Study Liver Diseases ( AASLD ) European Association Study Liver ( EASL ) describe detail approach algorithm diagnose Hepatocellular Carcinoma ( HCC ) . Eastern Cooperative Oncology Group ( ECOG ) Performance Status Score 0 2 Life expectancy ≥ 3 month &gt; 4 week since prior radiation , surgery chemotherapy Able comprehend provide consent accordance institutional federal guideline Any liver therapy plan cancer treatment Uncorrectable flow gastrointestinal tract Estimated radiation dose lung great 30 Gy single administration 50 Gy multiple administration Significant extrahepatic disease represent imminent lifethreatening outcome Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Humanitarian Device Exemption</keyword>
	<keyword>Liver Disease</keyword>
	<keyword>HDE # 980006</keyword>
</DOC>